<DOC>
	<DOCNO>NCT02618915</DOCNO>
	<brief_summary>A Phase 1/2 , open-label , dose-finding safety study single ascending dos DTX101 adult male moderate/severe severe hemophilia B .</brief_summary>
	<brief_title>Safety Dose Finding Study DTX101 ( AAVrh10FIX ) Adults With Moderate/Severe Severe Hemophilia B</brief_title>
	<detailed_description>Hemophilia B X-linked recessive genetic bleeding disorder cause mutation factor IX ( FIX ) gene . FIX produce liver critical fibrin clot formation . Hemophilia B characterize frequent , spontaneous internal bleeding lead chronic arthropathy ( joint damage ) , intracranial hemorrhage , even death . In patient moderate/severe severe hemophilia B , majority bleed episode occur joint , treat , lead debilitating damage decrease quality life . This study evaluate safety efficacy adeno-associated virus ( AAV ) deliver human factor IX ( hFIX ) gene , healthy gene necessary make FIX , liver FIX normally produce . This study determine AAVrh10 produce clinically meaningful FIX level patient moderately/severe severe hemophilia B .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>1 . Male ≥18 year age . 2 . Moderate/severe severe hemophilia B ( baseline FIX activity ≤2 % normal documented history FIX activity ≤2 % ) . 3 . At least 3 bleed episode per year require ondemand treatment FIX OR treat prophylactic regimen FIX . 4 . At least 100 day exposure history FIX . 5 . No documented history inhibitor ( neutralize antibody ) exogenous FIX . 6 . No known allergic reaction exogenous FIX component DTX101 . 7 . Willing stop prophylactic treatment recombinant FIX specify time point study . 1 . History significant liver disease ( ie ; portal hypertension ) . 2 . Significant hepatic inflammation cirrhosis . 3 . Evidence active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . 4 . History human immunodeficiency virus ( HIV ) infection AND following : CD4+ cell count &lt; 350 cells/mm3 , change antiretroviral therapy regimen within 6 month prior Day 0 , plasma viral load &gt; 200 copies/mL , 2 separate occasion , measure PCR . 5 . AntiAAVrh10 neutralize antibody titer &gt; 1:5 . 6 . Participation ( current previous ) another gene therapy study . 7 . Participation another investigational medicine study within 3 month screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>gene therapy</keyword>
	<keyword>Hemophilia B</keyword>
</DOC>